APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rifaximin Tablets

Compare research editions
View pricing & licenses

Selected research

Industry Research

Rifaximin Tablets Industry Research Report 2026

27 December 2025139 pages

Choose your research edition.

Industry ResearchRifaximin Tablets Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Rifaximin Tablets Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Rifaximin Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rifaximin Tablets Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Rifaximin Tablets Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Rifaximin Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Rifaximin Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Rifaximin Tablets is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Rifaximin Tablets is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Rifaximin Tablets include Aden Healthcare, Alfasigma SpA, AS Lifesciences, Estrellas Life Sciences Private Limited, Gnova Biotech, Healthy Life Pharma Pvt. Ltd., Netprime Pharma, Norgine Limited and Nanchang Feihong Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Rifaximin Tablets market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Rifaximin Tablets Market by Company

Aden Healthcare

Alfasigma SpA

AS Lifesciences

Estrellas Life Sciences Private Limited

Gnova Biotech

Healthy Life Pharma Pvt. Ltd.

Netprime Pharma

Norgine Limited

Nanchang Feihong Pharmaceutical Co., Ltd.

Shandong Zibo Xinda Pharmaceutical Co., Ltd.

Shaanxi Kaiyuan Pharmaceutical Co., Ltd.

Shenyang Tonglian Pharmaceutical Co., Ltd.

Sichuan Baili Pharmaceutical Co., Ltd.

Sichuan Mingxing Pharmaceutical Co., Ltd.

Tianjin Junan Biopharmaceutical Co., Ltd.

Chongqing Laimi Pharmaceutical Co., Ltd.

Chongqing Sino Biopharmaceutical Co., Ltd.

Rifaximin Tablets Segment by Type

0.1g

0.2g

Rifaximin Tablets Segment by Application

Clinic

Hospital

Other

Rifaximin Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifaximin Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rifaximin Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifaximin Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Rifaximin Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Rifaximin Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Rifaximin Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Rifaximin Tablets Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Rifaximin Tablets Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Rifaximin Tablets Sales Market Share by Manufacturers (2021-2026) Table 8. Global Rifaximin Tablets Revenue of Manufacturers (2021-2026) Table 9. Global Rifaximin Tablets Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Rifaximin Tablets Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Rifaximin Tablets Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Rifaximin Tablets, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Rifaximin Tablets, Product Type & Application Table 14. Global Rifaximin Tablets Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Rifaximin Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Aden Healthcare Company Information Table 19. Aden Healthcare Business Overview Table 20. Aden Healthcare Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Aden Healthcare Rifaximin Tablets Product Portfolio Table 22. Aden Healthcare Recent Developments Table 23. Alfasigma SpA Company Information Table 24. Alfasigma SpA Business Overview Table 25. Alfasigma SpA Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Alfasigma SpA Rifaximin Tablets Product Portfolio Table 27. Alfasigma SpA Recent Developments Table 28. AS Lifesciences Company Information Table 29. AS Lifesciences Business Overview Table 30. AS Lifesciences Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. AS Lifesciences Rifaximin Tablets Product Portfolio Table 32. AS Lifesciences Recent Developments Table 33. Estrellas Life Sciences Private Limited Company Information Table 34. Estrellas Life Sciences Private Limited Business Overview Table 35. Estrellas Life Sciences Private Limited Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Estrellas Life Sciences Private Limited Rifaximin Tablets Product Portfolio Table 37. Estrellas Life Sciences Private Limited Recent Developments Table 38. Gnova Biotech Company Information Table 39. Gnova Biotech Business Overview Table 40. Gnova Biotech Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Gnova Biotech Rifaximin Tablets Product Portfolio Table 42. Gnova Biotech Recent Developments Table 43. Healthy Life Pharma Pvt. Ltd. Company Information Table 44. Healthy Life Pharma Pvt. Ltd. Business Overview Table 45. Healthy Life Pharma Pvt. Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Healthy Life Pharma Pvt. Ltd. Rifaximin Tablets Product Portfolio Table 47. Healthy Life Pharma Pvt. Ltd. Recent Developments Table 48. Netprime Pharma Company Information Table 49. Netprime Pharma Business Overview Table 50. Netprime Pharma Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Netprime Pharma Rifaximin Tablets Product Portfolio Table 52. Netprime Pharma Recent Developments Table 53. Norgine Limited Company Information Table 54. Norgine Limited Business Overview Table 55. Norgine Limited Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Norgine Limited Rifaximin Tablets Product Portfolio Table 57. Norgine Limited Recent Developments Table 58. Nanchang Feihong Pharmaceutical Co., Ltd. Company Information Table 59. Nanchang Feihong Pharmaceutical Co., Ltd. Business Overview Table 60. Nanchang Feihong Pharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Nanchang Feihong Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 62. Nanchang Feihong Pharmaceutical Co., Ltd. Recent Developments Table 63. Shandong Zibo Xinda Pharmaceutical Co., Ltd. Company Information Table 64. Shandong Zibo Xinda Pharmaceutical Co., Ltd. Business Overview Table 65. Shandong Zibo Xinda Pharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Shandong Zibo Xinda Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 67. Shandong Zibo Xinda Pharmaceutical Co., Ltd. Recent Developments Table 68. Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Company Information Table 69. Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Business Overview Table 70. Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 72. Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Recent Developments Table 73. Shenyang Tonglian Pharmaceutical Co., Ltd. Company Information Table 74. Shenyang Tonglian Pharmaceutical Co., Ltd. Business Overview Table 75. Shenyang Tonglian Pharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Shenyang Tonglian Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 77. Shenyang Tonglian Pharmaceutical Co., Ltd. Recent Developments Table 78. Sichuan Baili Pharmaceutical Co., Ltd. Company Information Table 79. Sichuan Baili Pharmaceutical Co., Ltd. Business Overview Table 80. Sichuan Baili Pharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Sichuan Baili Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 82. Sichuan Baili Pharmaceutical Co., Ltd. Recent Developments Table 83. Sichuan Mingxing Pharmaceutical Co., Ltd. Company Information Table 84. Sichuan Mingxing Pharmaceutical Co., Ltd. Business Overview Table 85. Sichuan Mingxing Pharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sichuan Mingxing Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 87. Sichuan Mingxing Pharmaceutical Co., Ltd. Recent Developments Table 88. Tianjin Junan Biopharmaceutical Co., Ltd. Company Information Table 89. Tianjin Junan Biopharmaceutical Co., Ltd. Business Overview Table 90. Tianjin Junan Biopharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Tianjin Junan Biopharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 92. Tianjin Junan Biopharmaceutical Co., Ltd. Recent Developments Table 93. Chongqing Laimi Pharmaceutical Co., Ltd. Company Information Table 94. Chongqing Laimi Pharmaceutical Co., Ltd. Business Overview Table 95. Chongqing Laimi Pharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Chongqing Laimi Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 97. Chongqing Laimi Pharmaceutical Co., Ltd. Recent Developments Table 98. Chongqing Sino Biopharmaceutical Co., Ltd. Company Information Table 99. Chongqing Sino Biopharmaceutical Co., Ltd. Business Overview Table 100. Chongqing Sino Biopharmaceutical Co., Ltd. Rifaximin Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Chongqing Sino Biopharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio Table 102. Chongqing Sino Biopharmaceutical Co., Ltd. Recent Developments Table 103. Global Rifaximin Tablets Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Rifaximin Tablets Sales by Region (2021-2026) & (K Units) Table 105. Global Rifaximin Tablets Sales Market Share by Region (2021-2026) Table 106. Global Rifaximin Tablets Sales by Region (2027-2032) & (K Units) Table 107. Global Rifaximin Tablets Sales Market Share by Region (2027-2032) Table 108. Global Rifaximin Tablets Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Rifaximin Tablets Revenue Market Share by Region (2021-2026) Table 110. Global Rifaximin Tablets Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Rifaximin Tablets Revenue Market Share by Region (2027-2032) Table 112. North America Rifaximin Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Rifaximin Tablets Sales by Country (2021-2026) & (K Units) Table 114. North America Rifaximin Tablets Sales by Country (2027-2032) & (K Units) Table 115. North America Rifaximin Tablets Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Rifaximin Tablets Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Rifaximin Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Rifaximin Tablets Sales by Country (2021-2026) & (K Units) Table 119. Europe Rifaximin Tablets Sales by Country (2027-2032) & (K Units) Table 120. Europe Rifaximin Tablets Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Rifaximin Tablets Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Rifaximin Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Rifaximin Tablets Sales by Country (2021-2026) & (K Units) Table 124. Asia Pacific Rifaximin Tablets Sales by Country (2027-2032) & (K Units) Table 125. Asia Pacific Rifaximin Tablets Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Rifaximin Tablets Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Rifaximin Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Rifaximin Tablets Sales by Country (2021-2026) & (K Units) Table 129. South America Rifaximin Tablets Sales by Country (2027-2032) & (K Units) Table 130. South America Rifaximin Tablets Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Rifaximin Tablets Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Rifaximin Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Rifaximin Tablets Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa Rifaximin Tablets Sales by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Rifaximin Tablets Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Rifaximin Tablets Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Rifaximin Tablets Sales by Type (2021-2026) & (K Units) Table 138. Global Rifaximin Tablets Sales by Type (2027-2032) & (K Units) Table 139. Global Rifaximin Tablets Sales Market Share by Type (2021-2026) Table 140. Global Rifaximin Tablets Sales Market Share by Type (2027-2032) Table 141. Global Rifaximin Tablets Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Rifaximin Tablets Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Rifaximin Tablets Revenue Market Share by Type (2021-2026) Table 144. Global Rifaximin Tablets Revenue Market Share by Type (2027-2032) Table 145. Global Rifaximin Tablets Price by Type (2021-2026) & (US$/Unit) Table 146. Global Rifaximin Tablets Price by Type (2027-2032) & (US$/Unit) Table 147. Global Rifaximin Tablets Sales by Application (2021-2026) & (K Units) Table 148. Global Rifaximin Tablets Sales by Application (2027-2032) & (K Units) Table 149. Global Rifaximin Tablets Sales Market Share by Application (2021-2026) Table 150. Global Rifaximin Tablets Sales Market Share by Application (2027-2032) Table 151. Global Rifaximin Tablets Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Rifaximin Tablets Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Rifaximin Tablets Revenue Market Share by Application (2021-2026) Table 154. Global Rifaximin Tablets Revenue Market Share by Application (2027-2032) Table 155. Global Rifaximin Tablets Price by Application (2021-2026) & (US$/Unit) Table 156. Global Rifaximin Tablets Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Rifaximin Tablets Distributors List Table 160. Rifaximin Tablets Customers List Table 161. Rifaximin Tablets Industry Trends Table 162. Rifaximin Tablets Industry Drivers Table 163. Rifaximin Tablets Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Rifaximin Tablets Product Image Figure 5. Global Rifaximin Tablets Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Rifaximin Tablets Market Size (2021-2032) & (US$ Million) Figure 7. Global Rifaximin Tablets Sales (2021-2032) & (K Units) Figure 8. Global Rifaximin Tablets Average Price (US$/Unit) & (2021-2032) Figure 9. 0.1g Product Image Figure 10. 0.2g Product Image Figure 11. Clinic Product Image Figure 12. Hospital Product Image Figure 13. Other Product Image Figure 14. Global Rifaximin Tablets Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Rifaximin Tablets, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Rifaximin Tablets Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Rifaximin Tablets Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Rifaximin Tablets Sales by Region in 2025 Figure 20. Global Rifaximin Tablets Revenue by Region in 2025 Figure 21. North America Rifaximin Tablets Market Size by Country in 2025 Figure 22. North America Rifaximin Tablets Sales Market Share by Country (2021-2032) Figure 23. North America Rifaximin Tablets Revenue Market Share by Country (2021-2032) Figure 24. United States Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Rifaximin Tablets Market Size by Country in 2025 Figure 28. Europe Rifaximin Tablets Sales Market Share by Country (2021-2032) Figure 29. Europe Rifaximin Tablets Revenue Market Share by Country (2021-2032) Figure 30. Germany Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Rifaximin Tablets Market Size by Country in 2025 Figure 41. Asia Pacific Rifaximin Tablets Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Rifaximin Tablets Revenue Market Share by Country (2021-2032) Figure 43. China Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Rifaximin Tablets Market Size by Country in 2025 Figure 52. South America Rifaximin Tablets Sales Market Share by Country (2021-2032) Figure 53. South America Rifaximin Tablets Revenue Market Share by Country (2021-2032) Figure 54. Brazil Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Rifaximin Tablets Market Size by Country in 2025 Figure 58. Middle East and Africa Rifaximin Tablets Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Rifaximin Tablets Revenue Market Share by Country (2021-2032) Figure 60. Egypt Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Rifaximin Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Rifaximin Tablets Sales Market Share by Type (2021-2032) Figure 66. Global Rifaximin Tablets Revenue Market Share by Type (2021-2032) Figure 67. Global Rifaximin Tablets Price (US$/Unit) by Type (2021-2032) Figure 68. Global Rifaximin Tablets Sales Market Share by Application (2021-2032) Figure 69. Global Rifaximin Tablets Revenue Market Share by Application (2021-2032) Figure 70. Global Rifaximin Tablets Price (US$/Unit) by Application (2021-2032) Figure 71. Rifaximin Tablets Value Chain Figure 72. Rifaximin Tablets Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Rifaximin Tablets Industry Opportunities and Challenges

Scope & coverage.

Types
  • 0.1g
  • 0.2g
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Aden Healthcare
  • Alfasigma SpA
  • AS Lifesciences
  • Estrellas Life Sciences Private Limited
  • Gnova Biotech
  • Healthy Life Pharma Pvt. Ltd.
  • Netprime Pharma
  • Norgine Limited
  • Nanchang Feihong Pharmaceutical Co., Ltd.
  • Shandong Zibo Xinda Pharmaceutical Co., Ltd.
  • Shaanxi Kaiyuan Pharmaceutical Co., Ltd.
  • Shenyang Tonglian Pharmaceutical Co., Ltd.
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • Sichuan Mingxing Pharmaceutical Co., Ltd.
  • Tianjin Junan Biopharmaceutical Co., Ltd.
  • Chongqing Laimi Pharmaceutical Co., Ltd.
  • Chongqing Sino Biopharmaceutical Co., Ltd.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Rifaximin Tablets Market Size (2021-2032)
  4. 2.2.2 Global Rifaximin Tablets Sales (2021-2032)
  5. 2.2.3 Global Rifaximin Tablets Market Average Price (2021-2032)
  6. 2.3 Rifaximin Tablets by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 0.1g
  9. 2.3.3 0.2g
  10. 2.4 Rifaximin Tablets by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Clinic
  13. 2.4.3 Hospital
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Rifaximin Tablets Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Rifaximin Tablets Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Rifaximin Tablets Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Rifaximin Tablets Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Rifaximin Tablets Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Rifaximin Tablets, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Rifaximin Tablets, Product Type & Application
  8. 3.8 Global Manufacturers of Rifaximin Tablets, Established Date
  9. 3.9 Global Rifaximin Tablets Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Aden Healthcare
  2. 4.1.1 Aden Healthcare Company Information
  3. 4.1.2 Aden Healthcare Business Overview
  4. 4.1.3 Aden Healthcare Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Aden Healthcare Rifaximin Tablets Product Portfolio
  6. 4.1.5 Aden Healthcare Recent Developments
  7. 4.2 Alfasigma SpA
  8. 4.2.1 Alfasigma SpA Company Information
  9. 4.2.2 Alfasigma SpA Business Overview
  10. 4.2.3 Alfasigma SpA Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Alfasigma SpA Rifaximin Tablets Product Portfolio
  12. 4.2.5 Alfasigma SpA Recent Developments
  13. 4.3 AS Lifesciences
  14. 4.3.1 AS Lifesciences Company Information
  15. 4.3.2 AS Lifesciences Business Overview
  16. 4.3.3 AS Lifesciences Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 AS Lifesciences Rifaximin Tablets Product Portfolio
  18. 4.3.5 AS Lifesciences Recent Developments
  19. 4.4 Estrellas Life Sciences Private Limited
  20. 4.4.1 Estrellas Life Sciences Private Limited Company Information
  21. 4.4.2 Estrellas Life Sciences Private Limited Business Overview
  22. 4.4.3 Estrellas Life Sciences Private Limited Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Estrellas Life Sciences Private Limited Rifaximin Tablets Product Portfolio
  24. 4.4.5 Estrellas Life Sciences Private Limited Recent Developments
  25. 4.5 Gnova Biotech
  26. 4.5.1 Gnova Biotech Company Information
  27. 4.5.2 Gnova Biotech Business Overview
  28. 4.5.3 Gnova Biotech Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Gnova Biotech Rifaximin Tablets Product Portfolio
  30. 4.5.5 Gnova Biotech Recent Developments
  31. 4.6 Healthy Life Pharma Pvt. Ltd.
  32. 4.6.1 Healthy Life Pharma Pvt. Ltd. Company Information
  33. 4.6.2 Healthy Life Pharma Pvt. Ltd. Business Overview
  34. 4.6.3 Healthy Life Pharma Pvt. Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Healthy Life Pharma Pvt. Ltd. Rifaximin Tablets Product Portfolio
  36. 4.6.5 Healthy Life Pharma Pvt. Ltd. Recent Developments
  37. 4.7 Netprime Pharma
  38. 4.7.1 Netprime Pharma Company Information
  39. 4.7.2 Netprime Pharma Business Overview
  40. 4.7.3 Netprime Pharma Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Netprime Pharma Rifaximin Tablets Product Portfolio
  42. 4.7.5 Netprime Pharma Recent Developments
  43. 4.8 Norgine Limited
  44. 4.8.1 Norgine Limited Company Information
  45. 4.8.2 Norgine Limited Business Overview
  46. 4.8.3 Norgine Limited Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Norgine Limited Rifaximin Tablets Product Portfolio
  48. 4.8.5 Norgine Limited Recent Developments
  49. 4.9 Nanchang Feihong Pharmaceutical Co., Ltd.
  50. 4.9.1 Nanchang Feihong Pharmaceutical Co., Ltd. Company Information
  51. 4.9.2 Nanchang Feihong Pharmaceutical Co., Ltd. Business Overview
  52. 4.9.3 Nanchang Feihong Pharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Nanchang Feihong Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  54. 4.9.5 Nanchang Feihong Pharmaceutical Co., Ltd. Recent Developments
  55. 4.10 Shandong Zibo Xinda Pharmaceutical Co., Ltd.
  56. 4.10.1 Shandong Zibo Xinda Pharmaceutical Co., Ltd. Company Information
  57. 4.10.2 Shandong Zibo Xinda Pharmaceutical Co., Ltd. Business Overview
  58. 4.10.3 Shandong Zibo Xinda Pharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Shandong Zibo Xinda Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  60. 4.10.5 Shandong Zibo Xinda Pharmaceutical Co., Ltd. Recent Developments
  61. 4.11 Shaanxi Kaiyuan Pharmaceutical Co., Ltd.
  62. 4.11.1 Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Company Information
  63. 4.11.2 Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Business Overview
  64. 4.11.3 Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  66. 4.11.5 Shaanxi Kaiyuan Pharmaceutical Co., Ltd. Recent Developments
  67. 4.12 Shenyang Tonglian Pharmaceutical Co., Ltd.
  68. 4.12.1 Shenyang Tonglian Pharmaceutical Co., Ltd. Company Information
  69. 4.12.2 Shenyang Tonglian Pharmaceutical Co., Ltd. Business Overview
  70. 4.12.3 Shenyang Tonglian Pharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Shenyang Tonglian Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  72. 4.12.5 Shenyang Tonglian Pharmaceutical Co., Ltd. Recent Developments
  73. 4.13 Sichuan Baili Pharmaceutical Co., Ltd.
  74. 4.13.1 Sichuan Baili Pharmaceutical Co., Ltd. Company Information
  75. 4.13.2 Sichuan Baili Pharmaceutical Co., Ltd. Business Overview
  76. 4.13.3 Sichuan Baili Pharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Sichuan Baili Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  78. 4.13.5 Sichuan Baili Pharmaceutical Co., Ltd. Recent Developments
  79. 4.14 Sichuan Mingxing Pharmaceutical Co., Ltd.
  80. 4.14.1 Sichuan Mingxing Pharmaceutical Co., Ltd. Company Information
  81. 4.14.2 Sichuan Mingxing Pharmaceutical Co., Ltd. Business Overview
  82. 4.14.3 Sichuan Mingxing Pharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Sichuan Mingxing Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  84. 4.14.5 Sichuan Mingxing Pharmaceutical Co., Ltd. Recent Developments
  85. 4.15 Tianjin Junan Biopharmaceutical Co., Ltd.
  86. 4.15.1 Tianjin Junan Biopharmaceutical Co., Ltd. Company Information
  87. 4.15.2 Tianjin Junan Biopharmaceutical Co., Ltd. Business Overview
  88. 4.15.3 Tianjin Junan Biopharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Tianjin Junan Biopharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  90. 4.15.5 Tianjin Junan Biopharmaceutical Co., Ltd. Recent Developments
  91. 4.16 Chongqing Laimi Pharmaceutical Co., Ltd.
  92. 4.16.1 Chongqing Laimi Pharmaceutical Co., Ltd. Company Information
  93. 4.16.2 Chongqing Laimi Pharmaceutical Co., Ltd. Business Overview
  94. 4.16.3 Chongqing Laimi Pharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Chongqing Laimi Pharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  96. 4.16.5 Chongqing Laimi Pharmaceutical Co., Ltd. Recent Developments
  97. 4.17 Chongqing Sino Biopharmaceutical Co., Ltd.
  98. 4.17.1 Chongqing Sino Biopharmaceutical Co., Ltd. Company Information
  99. 4.17.2 Chongqing Sino Biopharmaceutical Co., Ltd. Business Overview
  100. 4.17.3 Chongqing Sino Biopharmaceutical Co., Ltd. Rifaximin Tablets Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Chongqing Sino Biopharmaceutical Co., Ltd. Rifaximin Tablets Product Portfolio
  102. 4.17.5 Chongqing Sino Biopharmaceutical Co., Ltd. Recent Developments
5 Global Rifaximin Tablets Market Scenario by Region
  1. 5.1 Global Rifaximin Tablets Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Rifaximin Tablets Sales by Region: 2021-2032
  3. 5.2.1 Global Rifaximin Tablets Sales by Region: 2021-2026
  4. 5.2.2 Global Rifaximin Tablets Sales by Region: 2027-2032
  5. 5.3 Global Rifaximin Tablets Revenue by Region: 2021-2032
  6. 5.3.1 Global Rifaximin Tablets Revenue by Region: 2021-2026
  7. 5.3.2 Global Rifaximin Tablets Revenue by Region: 2027-2032
  8. 5.4 North America Rifaximin Tablets Market Facts & Figures by Country
  9. 5.4.1 North America Rifaximin Tablets Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Rifaximin Tablets Sales by Country (2021-2032)
  11. 5.4.3 North America Rifaximin Tablets Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Rifaximin Tablets Market Facts & Figures by Country
  16. 5.5.1 Europe Rifaximin Tablets Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Rifaximin Tablets Sales by Country (2021-2032)
  18. 5.5.3 Europe Rifaximin Tablets Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Rifaximin Tablets Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Rifaximin Tablets Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Rifaximin Tablets Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Rifaximin Tablets Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Rifaximin Tablets Market Facts & Figures by Country
  41. 5.7.1 South America Rifaximin Tablets Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Rifaximin Tablets Sales by Country (2021-2032)
  43. 5.7.3 South America Rifaximin Tablets Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Rifaximin Tablets Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Rifaximin Tablets Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Rifaximin Tablets Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Rifaximin Tablets Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Rifaximin Tablets Sales by Type (2021-2032)
  2. 6.1.1 Global Rifaximin Tablets Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Rifaximin Tablets Sales Market Share by Type (2021-2032)
  4. 6.2 Global Rifaximin Tablets Revenue by Type (2021-2032)
  5. 6.2.1 Global Rifaximin Tablets Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Rifaximin Tablets Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Rifaximin Tablets Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Rifaximin Tablets Sales by Application (2021-2032)
  2. 7.1.1 Global Rifaximin Tablets Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Rifaximin Tablets Sales Market Share by Application (2021-2032)
  4. 7.2 Global Rifaximin Tablets Revenue by Application (2021-2032)
  5. 7.2.1 Global Rifaximin Tablets Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Rifaximin Tablets Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Rifaximin Tablets Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Rifaximin Tablets Value Chain Analysis
  2. 8.1.1 Rifaximin Tablets Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Rifaximin Tablets Production Mode & Process
  5. 8.2 Rifaximin Tablets Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Rifaximin Tablets Distributors
  8. 8.2.3 Rifaximin Tablets Customers
9 Global Rifaximin Tablets Analyzing Market Dynamics
  1. 9.1 Rifaximin Tablets Industry Trends
  2. 9.2 Rifaximin Tablets Industry Drivers
  3. 9.3 Rifaximin Tablets Industry Opportunities and Challenges
  4. 9.4 Rifaximin Tablets Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst